WO1995011235A1 - Pyrimidinones as antiarthritic and anti-inflammatories - Google Patents
Pyrimidinones as antiarthritic and anti-inflammatories Download PDFInfo
- Publication number
- WO1995011235A1 WO1995011235A1 PCT/US1994/010571 US9410571W WO9511235A1 WO 1995011235 A1 WO1995011235 A1 WO 1995011235A1 US 9410571 W US9410571 W US 9410571W WO 9511235 A1 WO9511235 A1 WO 9511235A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- oxo
- alkyl
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7511063A JPH09504010A (en) | 1993-10-20 | 1994-09-21 | Pyrimidinone as an anti-arthritic and anti-inflammatory agent |
AU77989/94A AU7798994A (en) | 1993-10-20 | 1994-09-21 | Pyrimidinones as antiarthritic and anti-inflammatories |
EP94928624A EP0724573A1 (en) | 1993-10-20 | 1994-09-21 | Pyrimidinones as antiarthritic and anti-inflammatories |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13907893A | 1993-10-20 | 1993-10-20 | |
US16167693A | 1993-12-03 | 1993-12-03 | |
US08/161,676 | 1993-12-03 | ||
US08/139,078 | 1993-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011235A1 true WO1995011235A1 (en) | 1995-04-27 |
Family
ID=26836841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/010571 WO1995011235A1 (en) | 1993-10-20 | 1994-09-21 | Pyrimidinones as antiarthritic and anti-inflammatories |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0724573A1 (en) |
JP (1) | JPH09504010A (en) |
AU (1) | AU7798994A (en) |
WO (1) | WO1995011235A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025596A2 (en) * | 1996-12-12 | 1998-06-18 | Pharmacia & Upjohn Company | Use of a 6-aryl pyrimidine compound for treating multiple sclerosis |
WO2004087677A2 (en) * | 2003-04-03 | 2004-10-14 | Pharmacia Corporation | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
EP1503993A2 (en) * | 2002-05-09 | 2005-02-09 | Cytokinetics, Inc. | Compounds, methods and compositions |
EP1509507A2 (en) * | 2002-05-23 | 2005-03-02 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
US7229993B2 (en) | 2002-03-13 | 2007-06-12 | Euro-Celtique S.A. | Aryl substituted pyrimidines and the use thereof |
US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
US7795271B2 (en) | 2003-04-03 | 2010-09-14 | Pharmacia Corporation | Substituted pyrimidinones |
US8324230B2 (en) | 2004-10-13 | 2012-12-04 | Pfizer Inc. | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
US20140248378A1 (en) * | 2011-07-07 | 2014-09-04 | Takeda Pharmaceutical Company Limited | Pyrimidinone compounds and their use |
WO2015036563A1 (en) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists |
WO2016113205A1 (en) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pentafluoroethyl pyrimidinones and use thereof |
US9434695B2 (en) | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
US9750748B2 (en) | 2012-12-17 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Pyridazinones as DAAO enzyme inhibitors |
US9902712B2 (en) | 2013-12-19 | 2018-02-27 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
US9931340B2 (en) | 2011-08-22 | 2018-04-03 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds and their use as DAAO inhibitors |
US10202399B2 (en) | 2011-11-15 | 2019-02-12 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
WO2021130492A1 (en) * | 2019-12-23 | 2021-07-01 | Sitryx Therapeutics Limited | Carboxy derivatives with antiinflammatory properties |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001198A1 (en) * | 1991-07-03 | 1993-01-21 | The Upjohn Company | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories |
EP0579425A1 (en) * | 1992-07-17 | 1994-01-19 | Rohm And Haas Company | 6-arylpyrimidines and herbicidal use thereof |
-
1994
- 1994-09-21 JP JP7511063A patent/JPH09504010A/en active Pending
- 1994-09-21 EP EP94928624A patent/EP0724573A1/en not_active Withdrawn
- 1994-09-21 WO PCT/US1994/010571 patent/WO1995011235A1/en not_active Application Discontinuation
- 1994-09-21 AU AU77989/94A patent/AU7798994A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001198A1 (en) * | 1991-07-03 | 1993-01-21 | The Upjohn Company | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories |
EP0579425A1 (en) * | 1992-07-17 | 1994-01-19 | Rohm And Haas Company | 6-arylpyrimidines and herbicidal use thereof |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025596A3 (en) * | 1996-12-12 | 1998-08-13 | Upjohn Co | Use of a 6-aryl pyrimidine compound for treating multiple sclerosis |
WO1998025596A2 (en) * | 1996-12-12 | 1998-06-18 | Pharmacia & Upjohn Company | Use of a 6-aryl pyrimidine compound for treating multiple sclerosis |
US7229993B2 (en) | 2002-03-13 | 2007-06-12 | Euro-Celtique S.A. | Aryl substituted pyrimidines and the use thereof |
EP1503993A2 (en) * | 2002-05-09 | 2005-02-09 | Cytokinetics, Inc. | Compounds, methods and compositions |
EP1503993A4 (en) * | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | Compounds, methods and compositions |
EP1509507A4 (en) * | 2002-05-23 | 2006-09-13 | Merck & Co Inc | Mitotic kinesin inhibitors |
EP1509507A2 (en) * | 2002-05-23 | 2005-03-02 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2004087677A3 (en) * | 2003-04-03 | 2004-12-16 | Pharmacia Corp | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
US7795271B2 (en) | 2003-04-03 | 2010-09-14 | Pharmacia Corporation | Substituted pyrimidinones |
AU2004226165B2 (en) * | 2003-04-03 | 2007-11-08 | Pharmacia Corporation | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
EA009743B1 (en) * | 2003-04-03 | 2008-04-28 | Фармация Корпорейшн | Pyrimidin-4-one derivatives and their use as p38kinase modulators |
AU2004226165C1 (en) * | 2003-04-03 | 2008-07-03 | Pharmacia Corporation | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
WO2004087677A2 (en) * | 2003-04-03 | 2004-10-14 | Pharmacia Corporation | Pyrimidin-4-one derivatives and their use as p38 kinase modulators |
US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
US8324230B2 (en) | 2004-10-13 | 2012-12-04 | Pfizer Inc. | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
US20140248378A1 (en) * | 2011-07-07 | 2014-09-04 | Takeda Pharmaceutical Company Limited | Pyrimidinone compounds and their use |
US10085986B2 (en) * | 2011-07-07 | 2018-10-02 | Takeda Pharmaceutical Company Limited | Pyrimidinone compounds and their use |
US10463663B2 (en) | 2011-08-22 | 2019-11-05 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds and their use as DAAO inhibitors |
US11129828B2 (en) | 2011-08-22 | 2021-09-28 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds and their use as DAAO inhibitors |
US9931340B2 (en) | 2011-08-22 | 2018-04-03 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds and their use as DAAO inhibitors |
US10202399B2 (en) | 2011-11-15 | 2019-02-12 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
US9434695B2 (en) | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
US9750748B2 (en) | 2012-12-17 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Pyridazinones as DAAO enzyme inhibitors |
WO2015036563A1 (en) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists |
US9902712B2 (en) | 2013-12-19 | 2018-02-27 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
WO2016113205A1 (en) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pentafluoroethyl pyrimidinones and use thereof |
WO2021130492A1 (en) * | 2019-12-23 | 2021-07-01 | Sitryx Therapeutics Limited | Carboxy derivatives with antiinflammatory properties |
Also Published As
Publication number | Publication date |
---|---|
JPH09504010A (en) | 1997-04-22 |
AU7798994A (en) | 1995-05-08 |
EP0724573A1 (en) | 1996-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0724573A1 (en) | Pyrimidinones as antiarthritic and anti-inflammatories | |
JP3526575B2 (en) | Phosphonic acid derivatives | |
US5635495A (en) | Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories | |
US5397774A (en) | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories | |
US5273990A (en) | Phosphono substituted tetrazole derivatives | |
US5550119A (en) | Phosphono substituted tetrazole derivatives as ECE inhibitors | |
US6706698B2 (en) | α-Substituted β-aminoethyl phosphonate derivatives | |
NZ225649A (en) | Preparation of unsaturated amino acid compounds, and pharmaceutical compositions | |
EP0660840B1 (en) | Phosphono substituted tetrazole derivatives | |
EP0654035B1 (en) | Phosphonoacetic esters and acids as anti-inflammatories | |
US5175344A (en) | Unsaturated amino acids | |
US20030114421A1 (en) | Alpha-substituted beta-aminoethyl phosphonate derivatives | |
US20020111488A1 (en) | Beta-substitued beta-aminoethyl phosphonate derivatives | |
US20050124581A1 (en) | Alpha-substituted heteroarylalkyl phosphonate derivatives | |
US20050124586A1 (en) | Alpha-substituted arylalkyl phosphonate derivatives | |
SI8811501A (en) | Process for the preparation of new unsaturated amino acide compounds | |
WO2004026242A2 (en) | Substituted ketophosphonate inhibitors of tumor cell proliferation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994928624 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 624561 Date of ref document: 19960409 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1994928624 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994928624 Country of ref document: EP |